Gerresheimer AG, a leading provider of healthcare and beauty solutions and drug delivery systems for pharma, biotech and cosmetics, is further accelerating its profitable growth. The strategic program of formula G is realigning the business with mega trends such as healthcare, sustainability and biotech. Three years in implementing formula G to foster sustainable profitable growth, Gerresheimer has beaten its revenue guidance in 2021. Last year the company generated EUR 1,497 million in core business revenues, achieving a strong organic growth of 7.6 percent. Core business adjusted EBITDA increased to EUR 324 million on a currency-adjusted basis meeting the forecast range.
“2021 was a record year of growth for us. The results show our strategy is paying off: We are turning Gerresheimer into the leading provider of innovative solutions and systems for the healthcare and beauty industry,” said Dietmar Siemssen, CEO of Gerresheimer AG. “We continue to invest in key growth areas and these investments are delivering excellent results. We grew High Value Solutions revenues by more than 30 percent. Biological Solutions increased by more than 40 percent. We started very strong into FY 2022, making significant progress in profitable, sustainable growth. We confirm for the running financial year to consistently deliver profitable high single-digit revenue growth and we raise our mid-term guidance: We will deliver an adjusted EBITDA margin of 23 to 25 percent for the Gerresheimer Group.”
To read the full announcement click here.
To read the annual report click here.